MedPath

Ketamine

Generic Name
Ketamine
Brand Names
Ketalar
Drug Type
Small Molecule
Chemical Formula
C13H16ClNO
CAS Number
6740-88-1
Unique Ingredient Identifier
690G0D6V8H
Background

Ketamine is an NMDA receptor antagonist with a potent anesthetic effect. It was developed in 1963 as a replacement for phencyclidine (PCP) by Calvin Stevens at Parke Davis Laboratories. It started being used for veterinary purposes in Belgium and in 1964 was proven that compared to PCP, it produced minor hallucinogenic effects and shorter psychotomimetic effects. It was FDA approved in 1970, and from there, it has been used as an anesthetic for children or patients undergoing minor surgeries but mainly for veterinary purposes.

Indication

Ketamine is indicated as an anesthetic agent for recommended diagnostic and surgical procedures. If skeletal muscle relaxation is needed, it should be combined with a muscle relaxant. If the surgical procedure involves visceral pain, it should be supplemented with an agent that obtunds visceral pain. Ketamine can be used for induction of anesthesia prior other general anesthetic agents and as a supplement of low potency agents.

Reports have indicated a potential use of ketamine as a therapeutic tool for the management of depression when administered in lower doses. These reports have increased the interest for ketamine in this area and several clinical trials are launched for this indication.

Associated Conditions
-
Associated Therapies
General Anesthesia, Induction and Maintenance of General Anesthesia

Postoperative Analgesia in Patients With Microvascular Decompression

Phase 4
Conditions
Trigeminal Neuralgia
Interventions
First Posted Date
2017-05-15
Last Posted Date
2018-05-15
Lead Sponsor
Xiangya Hospital of Central South University
Target Recruit Count
90
Registration Number
NCT03152955
Locations
🇨🇳

Xiangya Hospital of Central South University, Changsha, Hunan, China

A Study of Brexpiprazole Plus Ketamine in Treatment-Resistant Depression (TRD)

Phase 4
Completed
Conditions
Depression
Interventions
First Posted Date
2017-05-11
Last Posted Date
2020-07-24
Lead Sponsor
Massachusetts General Hospital
Target Recruit Count
51
Registration Number
NCT03149991
Locations
🇺🇸

Massachusetts General Hospital, Depression Clinical and Research Program, Boston, Massachusetts, United States

🇺🇸

Nathan Kline Institute for Psychiatric Research, Orangeburg, New York, United States

🇺🇸

Pacific Research Partners, LLC, Oakland, California, United States

and more 3 locations

Sedation During Spinal Anesthesia

Phase 2
Completed
Conditions
Sedation During Spinal Anesthesia
Interventions
First Posted Date
2017-04-28
Last Posted Date
2024-02-21
Lead Sponsor
Assiut University
Target Recruit Count
80
Registration Number
NCT03133780
Locations
🇪🇬

Faculty of Medicine Assuit University, Assiut, Asyut, Egypt

OFA - Opioid Free Anesthesia

Phase 4
Conditions
Postoperative Pain
Interventions
First Posted Date
2017-04-21
Last Posted Date
2017-04-21
Lead Sponsor
University of Parma
Target Recruit Count
64
Registration Number
NCT03124082
Locations
🇮🇹

University Hospital, Parma, Italy

Comparison of Opioid Based and Opioid Free Anaesthesia in Transsphenoidal Surgery

Not Applicable
Completed
Conditions
Opioid Free Anaesthesia
Interventions
First Posted Date
2017-04-19
Last Posted Date
2019-07-08
Lead Sponsor
Post Graduate Institute of Medical Education and Research, Chandigarh
Target Recruit Count
60
Registration Number
NCT03120234
Locations
🇮🇳

Post graduation institute of medical education and research, Chandigarh, India

ELEKT-D: Electroconvulsive Therapy (ECT) vs. Ketamine in Patients With Treatment Resistant Depression (TRD)

Phase 2
Completed
Conditions
Treatment Resistant Depression
Electroconvulsive Therapy
ECT
Ketamine
Psychiatric Disorder
Depression
Major Depressive Disorder
Major Depressive Episode
Unipolar Depression
Interventions
Procedure: electroconvulsive therapy (ECT)
Drug: Ketamine
First Posted Date
2017-04-14
Last Posted Date
2023-09-28
Lead Sponsor
Bo Hu
Target Recruit Count
403
Registration Number
NCT03113968
Locations
🇺🇸

Mount Sinai, New York, New York, United States

🇺🇸

Yale School of Medicine, New Haven, Connecticut, United States

🇺🇸

Johns Hopkins University School of Medicine, Baltimore, Maryland, United States

and more 2 locations

Intraoperative Low-dose Ketamine Infusion for Patients With Obstructive Sleep Apnea

Phase 2
Terminated
Conditions
Sleep Apnea
Obstructive Sleep Apnea
Postoperative Complications
Interventions
Procedure: Control
Drug: Ketamine
First Posted Date
2017-04-12
Last Posted Date
2019-12-19
Lead Sponsor
University of Alabama at Birmingham
Target Recruit Count
9
Registration Number
NCT03109418
Locations
🇺🇸

UAB Department of Anesthesiology and Perioperative Medicine, Birmingham, Alabama, United States

Acute and Chronic Pain, Especially Neuropathic Pain, After Thoracotomy and Continuous Application of Ketamine.

Not Applicable
Completed
Conditions
Neuropathic Pain
Acute Pain
Chronic Pain
Interventions
Drug: Placebo
Drug: Ketamine
First Posted Date
2017-04-10
Last Posted Date
2017-04-10
Lead Sponsor
Dr. Horst Schmidt Klinik GmbH
Target Recruit Count
200
Registration Number
NCT03105765
Locations
🇩🇪

Dr. Horst Schmidt Klinik, Wiesbaden, Hessen, Germany

Ketamine Versus Low Dose Thiopental for Induction of Anesthesia in Septic Shock

Phase 3
Completed
Conditions
Septic Shock
Interventions
First Posted Date
2017-04-07
Last Posted Date
2018-07-10
Lead Sponsor
Cairo University
Target Recruit Count
26
Registration Number
NCT03104140
Locations
🇪🇬

Cairo University, Cairo, Egypt

Ketamine and Nitroprusside for Depression

Phase 2
Completed
Conditions
Depression
Interventions
First Posted Date
2017-04-06
Last Posted Date
2020-07-02
Lead Sponsor
Icahn School of Medicine at Mount Sinai
Target Recruit Count
40
Registration Number
NCT03102736
Locations
🇺🇸

Icahn School of Medicine at Mount Sinai, New York, New York, United States

© Copyright 2025. All Rights Reserved by MedPath